Clinical study of early interventions for ABO hemolytic disease of the newborn.
- Author:
Wei-min HUANG
1
;
Hong-wu CHEN
;
Ning LI
;
Ming YANG
;
Pei-yan JIAO
Author Information
- Publication Type:Journal Article
- MeSH: ABO Blood-Group System; Bilirubin; blood; Erythroblastosis, Fetal; blood; drug therapy; immunology; Female; Humans; Immunoglobulins, Intravenous; administration & dosage; therapeutic use; Immunologic Factors; administration & dosage; therapeutic use; Infant, Newborn; Jaundice, Neonatal; drug therapy; Male; Time Factors; Treatment Outcome
- From: Journal of Southern Medical University 2006;26(9):1350-1355
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate therapeutic effect of high-dose intravenous immunoglobulin (IVIG) for early management of ABO hemolytic disease of the newborn (ABO-HDN).
METHODSA total of 121 cases with ABO-HDN were randomly divided into treatment group (n=61) and control group (n=60). In addition to the routine treatment of the control group, IVIG were given at a daily dose of 400 mg/kg to the cases in the treatment group for 2-3 times, and therapeutic effects were evaluated and compared between the two groups.
RESULTSThe serum total billirubin concentration on the third day after treatment (153.42-/+45.21 micromol/L) and mean daily serum total billirubin concentration reduction (56.49-/+24.05 micromol/L) in treatment group were lower than those in the control group (P<0.01). The jaundice resolution time (23.51-/+11.19 h) and the phototherapy time (3.01-/+0.89 h) for billirubinemia treatment in treatment group were shorter than those in the control group (P<0.01). The patients in the the treatment group had higher hemoglobin level after treatment (15.59-/+2.01 g/L) than those of the control group (P<0.01).
CONCLUSIONHigh-dose IVIG can effectively arrest the progression of hemolytic disease, quickly reduce serum total billirubin concentration and shorten phototherapy time for early treatment of ABO-HDN.
